Episurf Medical Ab Class B · OMXSTO:EPIS_B
Episurf Medical Ab Class B — Investor Presentation (February 2024)
25 slides from Episurf Medical Ab Class B's investor presentation, February 2024
Slide 1: Company Presentation
Company Presentation February 2024 episurf.com 1
Slide 2: Important information
Important information This company presentation (the “Company Presentation”) has been prepared by Episurf Medical AB (publ) (reg. no. 556767-0541) (the “Company” or “Episurf” and any reference to the Company or Episurf in this Company Presentation shall be understood to include the Company’s subsidi
Slide 3: Episurf at a glance
> Osteoarthritis – an ever-increasing burden to society with a significant treatment algorithm gap between biological repair and invasive joint replacement surgery > Episealer® – a comprehensive offering of implants across both knee and lower extremities individualized to patients’ anatomy > Broad I
Slide 4: Osteoarthritis – a global healthcare burden
Osteoarthritis – a global healthcare burden Disease manifestation1,2 Risk factors3 Average age of diagnosis4 Osteoarthritis (OA) is a chronic, progressive Main causes and risk factors include both systemic 55 degenerative disease that affects all parts of the and mechanical factors that increase sus
Slide 5: An unmet medical need – the Treatment Gap
An unmet medical need – the “Treatment Gap” Biological Repair Approaches that aim to promote 2m surgeries / year2 tissue repair and regeneration in the affected joints but are only applicable to young patients with Degree of Osteoarthritis (OA) early-stage OA. “Told to wait” / Painkillers / 700,000
Slide 6: Episurf's patients are all across the Treatment Gap
Episurf’s patients are all across the Treatment Gap 44-year-old 51-year-old 55-year-old cartilage small cartilage treated with triple degeneration on lesion and BML in implants – image the medial condyle Trochlea taken 12 months and in the trochlea post-op Despite several attempts, 39-year-old 63-ye
Slide 7: A new treatment option for a challenging population
A new treatment option for a challenging population Repeated biological procedures (microfacture (mfx), 63-year-old mosaicplasty, debridement, ACI… 57-year-oldsmall symptomatic Painkillers, told “to wait”… extended cartilage lesion on the 55-year-old degeneration on medial condyle Degree of Oste
Slide 8: Episealer® – a comprehensive technology platform
Episealer® – a comprehensive technology platform Knee Lower extremities Imaging platform • State-of-the-art imaging platform for Product patient selection Episealer® Knee Episealer® Patellofemoral Episealer® Talus Episealer® MTP-system • Used for design and System (with associated osteotomy guide) p
Slide 9: Individualized solutions to target unmet medical needs
Individualized solutions to target unmet medical needs Alternative Invasive arthroscopy or eye- Standardized off-the shelf Free-hand surgery with Cartilage lesions are often Stem and hat construction treatment balling on MRI scans implants and instrumentation standardized instruments related to unde
Slide 10: Wealth of clinical evidence validating Episurf's implants
Wealth of clinical evidence validating Episurf’s implants PRE-CLINICAL PROGRAMME CLINICAL STUDIES / PUBLICATIONS KEY TAKEAWAYS Product Study type Patients (n) Follow-up Highlights 5 preclinical > Extensive Consistent improvements Retrospective • 97.5% implant survival rate1 studies in animal (sheep)
Slide 11: Episealer® – accelerating adoption across geographies
Episealer® – accelerating adoption across geographies Close to 2,000 surgeries have taken place, with close to 500 patients having Episealer® implants for >5 years >10 Years 6 Years since >5 Years 474 Cumulative number of Episealer® implant surgery with >4 Years 687 orders from Jan. 2013 until Dec.
Slide 12: Focused positioning in the broader OA market
Focused positioning in the broader OA market 2022 2026 Knee Extremities • Approximately 365 million patients are affected by OA in the • As part of joint replacement solutions for OA, the extremities Aging Broader market knees globally1 segment make up about 4.8% of the broader orthopaedics market2
Slide 13: Near-term commercial opportunity
Near-term commercial opportunity Near-term market focus Long-term market focus First product Episealer® Knee in 510(k) cleared, Patellofemoral MTP Knee IDE trial for PMA 2nd product USA System System System process targeted launch 2024 Commercial Knee Talus activities Patellofemoral MTP EUROPE Syste
Slide 14: Efficient go-to-market strategy
Efficient go-to-market strategy Combination of strong clinical evidence, targeted product range and strategic local presence to efficiently capture the near-term 1 2 3 4 Regulatory Secure optimal Pricing & Sequential, Approval distribution & Reimbursement surgeon led representation Strategy adoption
Slide 15: Global KOL network
Global KOL network One of two levers for driving awareness and adoption amongst surgeons Professor Mats Brittberg (Sweden) Professor Karl Eriksson (Sweden) Professor, Cartilage Research Unit, Gothenburg University, Senior consultant orthopaedic surgeon, Stockholm South senior consultant orthopaedic
Slide 16: Global distributor network
Global distributor network One of two levers for driving awareness and adoption amongst surgeons ✓ Targeting distributors with Time should be spent on the patient… strong local presence and close ties to surgeon customers ”It is that our salesforce, like most orthopaedic salesforces, spends about 40
Slide 17: Capturing the European & RoW near-term opportunity
Capturing the European & RoW near-term opportunity Episealer® Knee Expanding distributor network • Launched, surgeons leading adoption in selected European Sweden, Norway, Denmark, Switzerland, UK, • • countries (Germany, Belgium & UK etc.) Technology adoption and clinical acceptance prioritized thr
Slide 18: Episealer® roll-out in the US underway
Episealer® roll-out in the US underway Securing reach in the US Episealer Patellofemoral System • • 510(k) cleared in December 2022, commercially launched H2 2023 ASP: USD ~4,500 23 40-50 Distributors Target no. of distributors • Focus on securing VAC approvals and initial customers across the count
Slide 19: Financial highlights
Financial highlights Year-end report 1 January – 31 December 2023 Gross order intake, LTM growth Surgeries per year 2020 2021 2022 2023 56% 500 53% 438 46% 400 39% 40% 36% +42.2% 306 26% 300 281 255 18% 19% 16% 11% 200 11% 7% 5% 5% 100 0% -4% -- J F M A M J J A S O N D Early technology establishment
Slide 20: Financial highlights (cont'd)
Financial highlights (cont’d) Year-end report 1 January – 31 December 2023 Q4 2023 vs. Q4 2022 FY 2023 vs. 2022 Q4 2023 Update +56.3% +40.9% Continued stable growth despite restructuring of commercial 11,1 organization, and satisfactory start in the US. 3,1 During the fourth quarter, 119 surgeries w
Slide 21: Management, Board of Directors & Senior Advisor
Management, Board of Directors & Senior Advisor Management Board of Directors & Senior Advisor Pål Ryfors, CEO Ulf Grunander B shares: 3,000,000 Employee Options: 872,734 Chairman of the Board Performance Options: 2,627,431 B shares: 381,000 Warrants: 1,661,427 Years with Episurf: 8 Leif Ryd Veronic
Slide 22: Episurf at a glance
> Osteoarthritis – an ever-increasing burden to society with a significant treatment algorithm gap between biological repair and invasive joint replacement surgery > Episealer® – a comprehensive offering of implants across both knee and lower extremities individualized to patients’ anatomy > Broad I
Slide 23: Appendix - List of publications (1/3)
Appendix - List of publications (1/3) Clinical publications Sports Traumatol Arthrosc, 2023. 31(4): p. 1247- 2021. 13(1_suppl): p. 1726S-1733S. (full publication) 1266. (full publication) • *Toom, D.A.d., et al., 2-year results of middle-aged • *Holz, J., et al., Patient-specific metal implants for
Slide 24: Appendix - List of publications (2/3)
Appendix - List of publications (2/3) Pre-clinical publications on opposing cartilage. A pilot study on 12 sheep. Osteoarthritis and Cartilage, 2013. 21(5): p. 739-745. (abstract) • * Schell, H., et al., Treatment of osteochondral defects: chondrointegration of metal implants improves after hydroxya
Slide 25: Appendix - List of publications (3/3)
Appendix - List of publications (3/3) Scientific publications • * Fuchs, A., et al., Focal metallic inlay resurfacing prosthesis for the treatment of localized cartilage defects of the femoral condyles: a systematic review of clinical studies. Knee Surgery, Sports Traumatology, Arthroscopy, 2017. (a
Episurf Medical — Investor Presentation (February 2024) on 6ix